Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Technical Presentation (April 2023)
10 slides from Sernova Biotherapeutics's technical presentation, Apr 24, 2023
Slide 1: In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell Pouch
In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell PouchTM Evotec International GmbH, IPITA workshop April 24/25, 2023
Slide 2: iPSC-derived islet-like clusters (ILCs) with long-term antidiabetic efficacy
iPSC-derived islet-like clusters (ILCs) with long-term antidiabetic efficacy Robust, durable normalization of glycemic control in diabetic mice Efficient normalization of random fed glucose Circulating hC-peptide by kidney capsule-implanted ILCs Evotec GMP manufacturing site near Modena/Italy • We h
Slide 3: Combining high quality iPSC-derived ILCs with a clinically proven device
Combining high quality iPSC-derived ILCs with a clinically proven device Evotec ILCs with Sernova Cell PouchTM • The Sernova Cell PouchTM is a pre- implanted, vascularized device providing an optimal environment for therapeutic cell function1 Accessible/retrievable implantation site • Sernova has
Slide 4: Testing the ILC + Cell Pouch combination in diabetic mice
Testing the ILC + Cell PouchTM combination in diabetic mice Sentinel-size Cell PouchTM in STZ-diabetic NSG mice with ILCs containing 1.7 x 106 beta cells Implant ILCs into Cell Pouch (1.7 x 106 β-cells) implant Cell PouchTM 1) hC- hC- end of inject peptide oGTT peptide oGTT exp./histology STZ 2 week
Slide 5: Excellent anti-diabetic activity of ILCs in the Cell Pouch
Excellent anti-diabetic activity of ILCs in the Cell PouchTM Rapid normalization of glycemic control with human islet-like potency Efficient normalization of random fed glucose Robust circulating hC-peptide levels Efficient glucose mouse glucose setpoint clearance and no hypoglycemias in oGTT (8 wee
Slide 6: High β-cell fraction and dense vascularization of ILCs in the Cell Pouch
High β-cell fraction and dense vascularization of ILCs in the Cell PouchTM Histological graft analysis – 32 weeks post-implantation INS • Abundant endocrine cells with high GCG beta cell fraction detectable SST DAPI • Alpha and delta cells are observed at lower frequencies INS CD31 DAPI • ILC cells
Slide 7: Excellent anti-diabetic activity of an ILC/Cell Pouch combination
Excellent anti-diabetic activity of an ILC/Cell PouchTM combination Summary • We have set up a scalable GMP manufacturing workflow from GMP iPS cells to ILCs, yielding a high beta cell fraction drug product ILCs are cryopreserved at a late intermediate stage Endocrine differentiation is complete
Slide 8: Matthias Austen, SVP Cell Therapy
Matthias Austen SVP Cell Therapy Matthias.Austen@evotec.eu
Slide 9: Testing the ILC + Cell Pouch combination in diabetic mice
Testing the ILC + Cell PouchTM combination in diabetic mice Sentinel-size Cell PouchTM in STZ-diabetic NSG mice with ILCs containing 1.7 x 106 beta cells Implant ILCs into Cell Pouch (1.7 x 106 β-cells) implant Cell PouchTM 1) hC- hC- end of inject peptide oGTT peptide oGTT exp./histology STZ 2 week
Slide 10: In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell Pouch
In vivo-testing of Evotec iPSC-derived islet-like clusters in the Sernova Cell PouchTM Evotec International GmbH, IPITA workshop April 24/25, 2023
Sernova Biotherapeutics — Technical Presentation (April 2023) on 6ix